Amniotic fluid embolism is a rare, catastrophic obstetric emergency characterized by sudden cardiopulmonary collapse, disseminated intravascular coagulation (DIC), and multi-organ failure during labor or within 30 minutes of delivery. Incidence is approximately 1.9–6.1 per 100,000 births, with case fatality rates of 11–50% depending on diagnostic criteria applied. [1-3] It is the fifth most common cause of direct maternal mortality worldwide. [4] The pathophysiology is now understood as an immune-mediated anaphylactoid reaction to fetal antigens (tissue factor, endothelin) rather than mechanical obstruction of pulmonary vasculature. [5-6]
1. History
- Onset is abrupt and unpredictable — typically during active labor, cesarean delivery, or within 30 minutes postpartum [1]
- Prodromal symptoms may include sudden dyspnea, agitation, anxiety, a sense of doom, shivering, or altered mental status before cardiovascular collapse [3-4]
- Ask about timing relative to labor events: rupture of membranes, amniotomy, placement of intrauterine pressure catheter, or delivery
- Sudden onset of frothy sputum may herald pulmonary edema [7]
- Fetal bradycardia may precede maternal symptoms and serve as an early warning sign [7]
- No reliable warning signs exist — many cases present as sudden cardiac arrest without prodrome [4]
2. Alarm Features
- Sudden cardiovascular collapse / cardiac arrest during labor or immediately postpartum [1][5]
- Acute severe hypoxia with cyanosis and respiratory failure
- Profuse hemorrhage with clinical evidence of DIC (oozing from IV sites, surgical wounds, mucosal surfaces) — DIC accompanies >80% of cases [1]
- Seizure-like activity or sudden loss of consciousness
- Pulseless electrical activity (PEA) is the most common arrest rhythm
- Fetal heart rate decelerations preceding maternal collapse [7]
- Any combination of the classic triad: hemodynamic instability + respiratory compromise + coagulopathy in the peripartum setting should trigger immediate AFE response [8]
3. Medications
Resuscitation medications (per SMFM and AHA guidelines)
- Vasopressor: Norepinephrine 0.05–3.3 μg/kg/min (preferred over fluid boluses) [1][9]
- Inotropes: Dobutamine 2.5–5.0 μg/kg/min or Milrinone 0.25–0.75 μg/kg/min [1]
- Pulmonary vasodilators: Inhaled nitric oxide 5–40 ppm, inhaled epoprostenol 10–50 ng/kg/min, IV epoprostenol 1–2 ng/kg/min, or sildenafil 20 mg PO (if awake) [1]
- Tranexamic acid (TXA): 1 g IV over 10 min for DIC/hemorrhage — supported by WOMAN trial data and SMFM recommendations [1][5]
- Uterotonics: Oxytocin prophylaxis plus additional agents (methylergonovine, carboprost, misoprostol) for uterine atony [1]
- Cryoprecipitate preferred over FFP to minimize volume overload; maintain fibrinogen >150–200 mg/dL [1][9]
Investigational — A-OK Protocol
- SMFM and experts caution against widespread adoption[10-11]
Contraindicated/Cautions
- Avoid excessive crystalloid resuscitation — worsens RV failure and pulmonary edema [1][9]
- Ketorolac (in A-OK) may worsen bleeding and renal function [10]
4. Diet
- Not applicable in the acute setting — patients are NPO and typically intubated
- Post-recovery ICU nutrition protocols apply per standard critical care guidelines
5. Review of Systems
- Cardiovascular: Chest pain, palpitations, syncope, sudden hypotension
- Respiratory: Acute dyspnea, cough with frothy sputum, cyanosis
- Neurologic: Seizures, altered mental status, loss of consciousness
- Hematologic: Bleeding from IV sites, surgical wounds, gums, vaginal hemorrhage disproportionate to expected postpartum blood loss
- Obstetric: Fetal heart rate abnormalities, uterine atony, placental abruption
6. Collateral History and Family History
- Obtain obstetric history from the labor team: timing of membrane rupture, use of oxytocin, amniotomy, intrauterine procedures
- Prior history of allergic or anaphylactoid reactions
- Family history is not a known contributor — AFE is not hereditary
- Social context: advanced maternal age, IVF conception may be relevant [12]
7. Risk Factors
- Maternal age ≥35 years (OR 1.86) [3]
- Cesarean section (OR 12.4) [3]
- Placenta previa (OR 10.5) [3]
- Multiple pregnancy (OR 8.5) [3]
- Placental abruption and placenta accreta spectrum — associated with highest failure-to-rescue rates (31–46%) [2]
- Operative vaginal delivery (forceps, vacuum) [13]
- Eclampsia, polyhydramnios, cervical lacerations, uterine rupture [13]
- Induction of labor and augmentation with oxytocin [4]
- However, many patients have no identifiable risk factors [4]
The following figure from a US population-based study illustrates how failure-to-rescue rates after AFE vary dramatically by clinical context, with placental pathology and advanced maternal age conferring the highest mortality:
8. Differential Diagnosis
The differential is critical because AFE is a diagnosis of exclusion: [4][8]
- Pulmonary thromboembolism — sudden dyspnea and cardiovascular collapse; distinguished by CT angiography if patient is stable enough
- Peripartum cardiomyopathy — heart failure typically develops over days/weeks, not seconds
- Anaphylaxis (to medications, latex) — urticaria, angioedema may be present; similar hemodynamic collapse
- Placental abruption with hemorrhagic shock — vaginal bleeding, uterine tenderness, fetal distress
- Uterine rupture — abdominal pain, loss of fetal station, hemorrhage
- Acute myocardial infarction / coronary dissection — ECG changes, troponin elevation
- Septic shock — fever, infectious source, typically more gradual onset
- Air embolism — associated with procedures, positioning
- High spinal / total spinal anesthesia — temporal relationship to neuraxial procedure
- Eclamptic seizure — hypertension, proteinuria, seizure without cardiovascular collapse
9. Past Medical History
- Prior AFE (extremely rare but reported)
- History of atopy or allergic conditions (theoretical association with anaphylactoid mechanism)
- Prior cesarean sections or uterine surgery
- Placental abnormalities in prior pregnancies
- Multiparity
- Chronic conditions affecting coagulation (thrombophilia, liver disease)
10. Physical Exam
Vital signs
- Profound hypotension or pulselessness
- Tachycardia → bradycardia → PEA arrest
- Hypoxia with SpO₂ dropping rapidly despite supplemental O₂
- Tachypnea progressing to apnea
Focused exam
- Cardiovascular: Jugular venous distension (RV failure), muffled heart sounds, signs of shock (cool/mottled extremities)
- Pulmonary: Bilateral crackles, frothy sputum, cyanosis
- Neurologic: Altered consciousness, seizures, fixed dilated pupils (if arrest)
- Obstetric: Uterine atony (boggy uterus), profuse vaginal hemorrhage, oozing from surgical sites/IV sites indicating DIC
- Skin: Petechiae, ecchymoses (coagulopathy)
11. Lab Studies
Immediate labs
- CBC — thrombocytopenia expected
- Coagulation panel: PT/INR, aPTT, fibrinogen (often profoundly low; target >150–200 mg/dL) [9]
- D-dimer — markedly elevated (nonspecific)
- Viscoelastic testing (TEG/ROTEM) — preferred for rapid assessment of hyperfibrinolysis; proposed as diagnostic aid [1][5]
- ABG/VBG — metabolic acidosis, hypoxemia, hypercapnia
- Lactate — elevated in shock
- Type and crossmatch — immediate; anticipate massive transfusion
- Troponin — may be elevated (myocardial injury)
- BMP, LFTs — assess for multi-organ dysfunction
No confirmatory biomarker exists — diagnosis remains clinical. [6][8] Serum tryptase, complement levels (C3, C4), and insulin-like growth factor binding protein-1 (IGFBP-1) have been investigated but are not validated. [8]
12. Imaging
- Bedside echocardiography (TTE or TEE) — first-line and most important imaging [1][9]
- Findings: Acute RV dilation, RV failure, increased pulmonary vascular resistance, interventricular septal bowing, reduced LV filling
- Guides vasopressor/inotrope/pulmonary vasodilator therapy
- Chest X-ray — bilateral pulmonary edema (nonspecific); often impractical during resuscitation
- CT pulmonary angiography — only if stable enough; primarily to exclude pulmonary thromboembolism
- Point-of-care ultrasound (POCUS) — assess IVC, cardiac function, free fluid
- Imaging is secondary to resuscitation — should not delay treatment
13. Special Tests
- Thromboelastography (TEG) / Rotational thromboelastometry (ROTEM) — rapid identification of hyperfibrinolysis; guides transfusion and TXA administration [1][5]
- Bedside echocardiography — as above, critical for identifying RV failure pattern
- Postmortem diagnosis: Histological or immunohistochemical demonstration of fetal squamous cells, mucin, or lanugo hair in pulmonary vasculature — establishes definitive diagnosis at autopsy [3]
- No validated clinical scoring system exists for AFE diagnosis; proposed research criteria by Clark et al. require the classic triad (hemodynamic compromise + respiratory compromise + DIC) with onset during labor or within 30 min of delivery and absence of other explanations [8]
14. ECG
- Sinus tachycardia → progressing to bradycardia
- Right heart strain pattern: Right axis deviation, S1Q3T3, RV strain with ST changes in V1–V4
- PEA is the most common arrest rhythm in AFE
- ST-segment changes may mimic acute MI (coronary vasospasm or demand ischemia)
- Arrhythmias including ventricular tachycardia/fibrillation may occur [3]
- ECG helps exclude primary cardiac events (STEMI, arrhythmia) as the cause of collapse
15. Assessment
AFE presents as a biphasic hemodynamic response: [13]
- Phase 1 (minutes): Acute pulmonary hypertension → RV failure → cardiogenic shock → cardiac arrest
- Phase 2 (if survival): LV failure with pulmonary edema + DIC with massive hemorrhage
Severity stratification
- Classic/severe AFE: Cardiac arrest + DIC + hemorrhage — mortality 38–50% [1-2]
- Atypical/partial AFE: Isolated coagulopathy or hemodynamic instability without full triad — lower mortality but still significant [2]
- Complications: Multi-organ dysfunction (ARDS, AKI, hepatic failure), neurologic injury from hypoxia, hysterectomy, neonatal morbidity/mortality
16. Treatment Plan
The following management algorithm from Critical Care Obstetrics illustrates the simultaneous, multidisciplinary approach required:
Immediate stabilization (per AHA 2025 and SMFM guidelines): [1][5]
- ABCs and CPR — high-quality chest compressions with manual left uterine displacement
- Resuscitative hysterotomy — begin within 4 minutes of pulseless arrest if no ROSC; goal is maternal resuscitation (do not wait for antibiotics, splash prep only) [1]
- Secure airway — early intubation; 100% FiO₂
Hemodynamic support
- Vasopressor: Norepinephrine 0.05–3.3 μg/kg/min (preferred over fluids) [1]
- Inotropes: Dobutamine 2.5–5.0 μg/kg/min or Milrinone 0.25–0.75 μg/kg/min [1]
- Pulmonary vasodilators: Inhaled nitric oxide 5–40 ppm or inhaled epoprostenol [1]
- Avoid fluid overload — use 500 mL boluses and reassess; prefer blood products over crystalloid [1]
Coagulopathy management
- Activate massive transfusion protocol — 1:1:1 ratio of pRBCs:FFP:platelets [5][9]
- Cryoprecipitate preferred over FFP to reduce volume overload; target fibrinogen >150–200 mg/dL [1][9]
- TXA 1 g IV over 10 min — supported by WOMAN trial and SMFM [1][5]
- Guide transfusion with TEG/ROTEM if available [1]
Refractory cases
17. Disposition
- All patients require ICU admission — no exceptions [1]
- Multidisciplinary team: OB, anesthesiology, critical care, hematology, cardiology, neonatology, and potentially cardiac surgery (for ECMO) [6]
- Transfer to a higher-level center with ECMO capability if refractory to medical management and not already at such a facility [5][15]
- Neonatal team should be present for delivery given high perinatal morbidity
18. Follow Up / Return Precautions
- ICU monitoring for ongoing DIC, hemorrhage, ARDS, AKI, and hepatic dysfunction — organ failure may evolve over 24–72 hours [16]
- Wean FiO₂ to maintain SpO₂ 94–98% [1]
- Monitor for secondary complications: venous thromboembolism (after coagulopathy resolves), infection, Sheehan syndrome
- Psychological support for patient, family, and clinical staff — post-event debriefing recommended by SMFM [1]
- Report case to the Amniotic Fluid Embolism Foundation Registry [1]
- Long-term follow-up: assess for neurologic sequelae (hypoxic brain injury), cardiac function recovery, and psychological trauma (PTSD)
- Survivors should receive counseling regarding future pregnancies — recurrence risk is unknown but considered very low; no established contraindication to future pregnancy, though shared decision-making is essential
References
1. Society for Maternal-Fetal Medicine Special Statement: Checklist for Initial Management of Amniotic Fluid Embolism. — Combs CA, Montgomery DM, Toner LE, Dildy GA. American Journal of Obstetrics and Gynecology. 2021.
2. Association of Pregnancy Characteristics and Maternal Mortality With Amniotic Fluid Embolism. — Mazza GR, Youssefzadeh AC, Klar M, et al. JAMA Network Open. 2022.
3. Amniotic Fluid Embolism: An Interdisciplinary Challenge: Epidemiology, Diagnosis and Treatment. — Rath WH, Hoferr S, Sinicina I. Deutsches Arzteblatt International. 2014.
4. Amniotic Fluid Embolism. — Moore J, Baldisseri MR. Critical Care Medicine. 2005.
5. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
6. Amniotic Fluid Embolism: A Comprehensive Review of Diagnosis and Management. — Andonotopo W, Bachnas MA, Dewantiningrum J, et al. Journal of Perinatal Medicine. 2025.
7. Successful Management of Amniotic Fluid Embolism With Cardiac Arrest and Liver Rupture: A Case Report. — Liu J, Ma S, Wang Y, Wei F. Frontiers in Medicine. 2025.
8. Proposed Diagnostic Criteria for the Case Definition of Amniotic Fluid Embolism in Research Studies. — Clark SL, Romero R, Dildy GA, et al. American Journal of Obstetrics and Gynecology. 2016.
9. Amniotic Fluid Embolism: Principles of Early Clinical management. — Pacheco LD, Clark SL, Klassen M, Hankins GDV. American Journal of Obstetrics and Gynecology. 2020.
10. Use of Atropine, Ondansetron, and Ketorolac in Suspected Amniotic Fluid Embolism. — Pacheco LD, Clark SM, Fox K, Bauer ME, Clark SL. Obstetrics and Gynecology. 2025.
11. Early Application of Modified a-Ok Protocol for Amniotic Fluid Embolism: Case Series Report. — He S, Tao B. Medicine. 2025.
12. Amniotic Fluid Embolism: A Reappraisal. — Young BK, Florine Magdelijns P, Chervenak JL, Chan M. Journal of Perinatal Medicine. 2024.
13. Amniotic Fluid Embolism: An Evidence-Based Review. — Conde-Agudelo A, Romero R. American Journal of Obstetrics and Gynecology. 2009.
14. Amniotic Fluid Embolism. — Gary A. Dildy, Michael A. Belfort, Steven L. Clark Critical Care Obstetrics, 7th Edition. 2024.
15. The Importance of Early Veno-Arterial Extracorporeal Membrane Oxygenation in the Management of Amniotic Fluid Embolism Complicated by Cardiac Arrest: A Case Report and Literature Review. — Su J, Luo J, Chen H, et al. BMC Pregnancy and Childbirth. 2025.
16. Amniotic Fluid Embolism Complicated by Pulmonary Embolism Leading to Multiple Organ Dysfunction: Case Report. — Liu M, Li C, Mei H, et al. Frontiers in Medicine. 2026.